Improving cross ancestry polygenic prediction of tobacco and alcohol use
改进烟草和酒精使用的跨血统多基因预测
基本信息
- 批准号:10739557
- 负责人:
- 金额:$ 16.01万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-01 至 2028-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdoptionAffectAfricanAlcohol consumptionAlcoholsAll of Us Research ProgramAmericanAwardBehaviorBehavioral GeneticsBioethicsClinicalComplexCoupledDataData DiscoveryData SetDemographic FactorsDistantDrug AddictionDrug usageEast AsianEquityEuropeanEuropean ancestryExclusionGene ExpressionGene FrequencyGenesGeneticGenetic ResearchGenetic RiskGenetic VariationGenetic studyGenomicsGenotypeGoalsHealth Care CostsHeritabilityHeterogeneityHumanIndividualLife StyleLinkage DisequilibriumMedicalMental disordersMentorsMentorshipMeta-AnalysisMethodsModelingNational Institute of Drug AbuseParticipantPerformancePersonsPhenotypePopulationPopulation GeneticsPreventionPsychologyPublic HealthResearchRiskSample SizeSamplingScientistSiblingsSmokingSourceStructureSubstance of AbuseTechnologyTobaccoTobacco useTrainingTrans-Omics for Precision MedicineUnited StatesVariantVeteransWorkaddictionbiobankcareercohortcostdisorder riskdrug use behavioreffective therapyethical, legal, and social implicationexomefunctional genomicsgenetic architecturegenetic associationgenetic variantgenome sequencinggenome wide association studygenomic predictorshealth disparityimprovedindividualized preventioninstrumentinterestnicotine usepolygenic risk scoreportabilityprecision medicinepreventable deathrare variantrisk predictionrisk stratificationscreeningstatisticssubstance usesubstance use treatmenttraitwhole genome
项目摘要
Project Summary/Abstract
Tobacco and alcohol are the most commonly used substances of abuse, resulting in heavy personal and public
health costs. The ability to identify risk prior to substance initiation has important potential to inform prevention
efforts and tailor more effective treatments through precision medicine approaches. Continuing technological
progress and reduced costs of genotyping have resulted in very large sample sizes in genetic association
studies, findings of which have allowed for the prediction of individual genetic risk, through polygenic risk scores.
These results have ignited interest in the use of polygenic scores to inform personalized prevention efforts,
population-level screening, and as statistical controls or genetic instruments within research. The incorporation
of polygenic scores in clinical and research settings shows promise, however there are several limitations to their
current use including modest predictive accuracy and limited portability across populations. The proposed
research will leverage a trans-ancestry genome-wide association study of tobacco and alcohol use in 3.4 million
individuals, combined with ~2.5 million additional participants with microarray, exome, or whole-genome
sequencing data to improve polygenic prediction of substance use behaviors and to maximize predictive
accuracy of such scores across individuals of diverse genetic ancestries. There are two major research aims: 1)
to pool large cohorts of diverse ancestry genetic studies that include information on common and rare genetic
variation, and gene expression, to improve genomic risk prediction for substance use, and 2) evaluate and
correct for the sources of reduced cross-ancestry portability of polygenic scores in order to increase their utility
with higher predictive accuracy across all genetic ancestries. To accomplish these research aims and to achieve
the goal of an independent research career, this proposal includes new mentored training in 1) advanced and
functional genomics, 2) advanced statistic and population genetics, 3) ethical, legal, and social implications
(ELSI) of genetic research. This proposal directly aligns with NIDA’s goals to identify the genetic mechanisms
that influence substance use and to use this research to address health disparities. The candidate will receive
extensive mentorship and guidance with a team of leading experts in the fields of addiction, genetics, and
bioethics. The training and support provided by this award will facilitate the candidate’s long-term career goal as
an independent research scientist, building on her background in quantitative psychology, drug addiction, and
behavioral genetics. The proposed research, coupled with the candidate’s research potential, has the ability to
greatly expand the personal, clinical, and research utility of genomic prediction and to refine our understanding
of the genetic architecture of substance use.
项目总结/摘要
烟草和酒精是最常用的滥用物质,导致严重的个人和公共
医疗费用。在开始使用药物之前识别风险的能力对于预防具有重要的潜在意义
通过精准医疗方法,努力定制更有效的治疗方法。到方兴未艾的技术
基因分型的进步和成本的降低导致了遗传关联的非常大的样本量
研究结果允许通过多基因风险评分预测个体遗传风险。
这些结果激发了人们对使用多基因评分来告知个性化预防工作的兴趣,
人口水平的筛选,并作为统计控制或遗传工具的研究。掺入
多基因评分在临床和研究环境中的应用显示出希望,然而,其存在一些局限性。
目前的使用包括适度的预测准确性和有限的跨人群的便携性。拟议
研究将利用340万人的烟草和酒精使用的跨祖先全基因组关联研究
个体,结合约250万额外参与者的微阵列,外显子组或全基因组
测序数据,以改善对物质使用行为的多基因预测,
这些分数在不同遗传祖先的个体中的准确性。本研究的主要目的有二:1)
汇集大量不同祖先的遗传研究,包括常见和罕见的遗传信息,
变异和基因表达,以改善物质使用的基因组风险预测,以及2)评估和
校正多基因评分跨祖先可移植性降低的来源,以增加其实用性
在所有遗传祖先中具有更高的预测准确性。为了实现这些研究目标,
作为一个独立的研究生涯的目标,这项建议包括新的指导培训1)先进的,
功能基因组学,2)先进的统计学和人口遗传学,3)伦理,法律的和社会影响
(ELSI)基因研究。这一建议直接符合NIDA的目标,以确定遗传机制,
并利用这项研究来解决健康差距。候选人将获得
广泛的指导和指导与领先的专家团队在成瘾,遗传学,
生命伦理学该奖项提供的培训和支持将促进候选人的长期职业目标,
一位独立的研究科学家,建立在她在定量心理学,药物成瘾,
行为遗传学拟议的研究,加上候选人的研究潜力,有能力,
极大地扩展了基因组预测的个人,临床和研究效用,并完善了我们的理解
药物使用的遗传结构。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Gretchen Saunders其他文献
Gretchen Saunders的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
- 批准号:
10093543 - 财政年份:2024
- 资助金额:
$ 16.01万 - 项目类别:
Collaborative R&D
Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
- 批准号:
24K16436 - 财政年份:2024
- 资助金额:
$ 16.01万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
- 批准号:
24K16488 - 财政年份:2024
- 资助金额:
$ 16.01万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 16.01万 - 项目类别:
EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
- 批准号:
24K20973 - 财政年份:2024
- 资助金额:
$ 16.01万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 16.01万 - 项目类别:
EU-Funded
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
- 批准号:
10075502 - 财政年份:2023
- 资助金额:
$ 16.01万 - 项目类别:
Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
- 批准号:
10089082 - 财政年份:2023
- 资助金额:
$ 16.01万 - 项目类别:
EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
- 批准号:
481560 - 财政年份:2023
- 资助金额:
$ 16.01万 - 项目类别:
Operating Grants
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
- 批准号:
2321091 - 财政年份:2023
- 资助金额:
$ 16.01万 - 项目类别:
Standard Grant